Orum Therapeutics to Relaunch Initial Public Offering Next Year

• Strategic decision reflecting market conditions 

Orum Therapeutics (“Orum”) will resume its listing on the KOSDAQ market next year.  

On November 29, Orum announced that it has postponed its initial public offering (IPO) plan that was scheduled for next month. The company had been preparing for the listing after submitting its securities registration statement.

“We have made the decision to postpone the public listing considering the current market situation, which is in the best interest of our stakeholders. We will continue to fulfill our mission of developing innovative drugs for patients in need,” said Sung Joo Lee, Ph.D., CEO of Orum Therapeutics.

About Orum Therapeutics 

Orum Therapeutics is a private, clinical-stage biotech pioneering the development of the cell-specific, targeted protein degraders (TPD²) approach, which combines the precision of antibody targeting technology. Orum is located in Lexington, MA, US, and Daejeon, South Korea. For more info, please visit www.orumrx.com.